Cooper Companies Securities Investigation After Guidance Cut
Analysis based on 26 articles · First reported Sep 11, 2026 · Last updated Sep 23, 2026
The revenue miss and sharply reduced guidance triggered a nearly 15% single-day decline in COO shares, reflecting investor concern over demand visibility and channel inventory management at The Cooper Companies — CooperVision. The pending securities investigation adds legal and reputational overhang, though its near-term market impact is limited to COO and its shareholders rather than the broader medical device sector.
The Cooper Companies reported third-quarter fiscal 2026 revenue of approximately $1.07 billion, missing analyst consensus of roughly $1.10 billion, driven primarily by proactive U.S. channel destocking at its The Cooper Companies — CooperVision segment. The Cooper Companies — CooperVision revenue came in at approximately $717 million, essentially flat year-over-year and below consensus. Management sharply reduced full-year revenue guidance from a prior projection of $4.285-$4.321 billion (organic growth of 3.5%-4.5%) to $4.229-$4.252 billion (organic growth of 2%-3%), and guided The Cooper Companies — CooperVision to negative 2% to flat organic growth for the fourth quarter. CEO Albert White attributed the entire guidance reduction to channel inventory, stating the company proactively reduced U.S. channel inventory and would return to growth tied to consumption. Shares fell nearly 15% following the disclosure on September 9, 2026, despite adjusted earnings per share of $1.15 topping the $1.12 consensus. Analyst downgrades and price-target cuts followed. Levi & Korsinsky, LLP subsequently commenced an investigation into whether The Cooper Companies adequately disclosed the impact of U.S. channel inventory reductions and destocking at The Cooper Companies — CooperVision ahead of the revenue shortfall, and whether the company made materially false or misleading statements regarding demand trends, inventory levels, and growth outlook. The investigation is pending and no legal action has been filed. Investors who purchased COO securities and suffered losses are encouraged to contact Joseph E. Levi, Esq. for a no-cost review.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard